TELO
NASDAQ · Pharmaceuticals
Telomir Pharmaceuticals Inc
$1.28
+0.00 (+0.00%)
Financial Highlights (FY 2025)
Revenue
9.55M
Net Income
1.76M
Gross Margin
60.2%
Profit Margin
18.4%
Rev Growth
-2.0%
D/E Ratio
0.60
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 60.2% | 60.2% | 60.2% |
| Operating Margin | 20.1% | 21.4% | 21.0% |
| Profit Margin | 18.4% | 20.1% | 17.9% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.55M | 10.11M | 8.56M |
| Gross Profit | 5.75M | 6.09M | 5.16M |
| Operating Income | 1.92M | 2.16M | 1.80M |
| Net Income | 1.76M | 2.03M | 1.53M |
| Gross Margin | 60.2% | 60.2% | 60.2% |
| Operating Margin | 20.1% | 21.4% | 21.0% |
| Profit Margin | 18.4% | 20.1% | 17.9% |
| Rev Growth | -2.0% | +7.8% | +19.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 12.07M | 12.41M | 14.16M |
| Total Equity | 20.19M | 17.62M | 20.98M |
| D/E Ratio | 0.60 | 0.70 | 0.67 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 2.43M | 2.63M | 2.21M |
| Free Cash Flow | 1.02M | 1.59M | 1.30M |